title: Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
authors.forename: Michael C
authors.initials: MC
authors.lastname: Donohue
authors.forename: Anthony C
authors.initials: AC
authors.lastname: Gamst
authors.forename: Paul S
authors.initials: PS
authors.lastname: Aisen
mesh_terms: D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000134:cerebrospinal fluid* / Q000188:drug therapy*; D006801:Humans; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D012107:Research Design
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)